Dear Editor,

We read with great interest the recent article by Perico et al. \[[@B1]\] on COVID-19 and kidney involvement.

The authors reported that acute kidney injury (AKI) is one of most common comorbidities of COVID-19 \[[@B2]\]. However, previous reports showed that viruses of the Coronaviridae family differently affected the kidney: AKI was present in only 6% of patients with SARS coronavirus (SARS-CoV) infection \[[@B1]\], in 75% of patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection \[[@B3]\], and in 25% of patients with SARS-CoV2 infection \[[@B4]\]. In all cases, AKI was identified as a fatal complication.

The different rates of renal involvement were independent of coronavirus renal tropism, since SARS-CoV and Sars-CoV2, and MERS-CoV receptors (ACE2 and DPP-4, respectively) are equally expressed in renal epithelium \[[@B5]\]. In particular, MERS-CoV showed a direct cytopathic effect on renal epithelial cells \[[@B4]\]. In contrast, SARS-CoV was associated with acute tubular necrosis without signs of glomerulopathy \[[@B1]\], and without in vitro cytopathic effect on renal epithelial cells; renal impairment was likely due to specific pathogenic conditions, including cytokine release syndrome, rather than active viral replication in the kidney, and was related to multi-organ failure \[[@B3]\].

Interestingly, subjects infected with SARS-CoV2 seem to be affected by AKI more frequently than subjects infected with SARS-CoV (25%) \[[@B2]\], despite the same human receptors (ACE2). Perhaps an increased affinity of SARS-CoV2 for ACE2 could explain its higher renal tropism \[[@B5]\]. A recent study showed that SARS-COV2 antigens accumulated in kidney tubules, suggesting that it is able to directly affect kidney cells. These data are consistent with the high prevalence (40%) of kidney injury, such as proteinuria and haematuria, at hospital admission of COVID-19 patients \[[@B2]\].

Therefore, given the role of AKI as a fatal comorbidity for COVID-19, and the frequent presence of renal signs in the early phase of the infection, we recommend early monitoring of renal involvement in these patients.
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